<DOC>
	<DOCNO>NCT00016185</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine flavopiridol docetaxel treat patient advance solid tumor .</brief_summary>
	<brief_title>Flavopiridol Docetaxel Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose-limiting toxic effect maximum tolerate dose flavopiridol docetaxel patient advance solid tumor . - Determine objective response rate duration response patient treat regimen . - Determine pharmacokinetics drug patient population . OUTLINE : This dose-escalation study . Patients receive docetaxel IV 60 minute day 1 flavopiridol IV continuously 24 hour day 2 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos docetaxel flavopiridol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 18-24 patient accrue study within 9-11 month .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic unresectable solid tumor No standard relatively effective curative palliative measure exist Measurable disease least 1 dimension At least 20 mm conventional technique OR least 10 mm spiral CT scan No known clinically active uncontrolled brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Karnofsky 60100 % Life expectancy : More 12 week Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal ALT/AST great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Renal : Creatinine normal Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No prior allergic reaction compound similar chemical biologic composition flavopiridol docetaxel No uncontrolled concurrent illness would preclude study participation No ongoing active infection No psychiatric illness social situation would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : At least 6 month since prior taxane therapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except contraceptive , appetite stimulant , replacement steroid Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics Other : No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>